The susceptibility of humans to obesity is far higher compared with other species and in man favours the deposition of fat. Amongst mammals humans have reported to have the highest levels of fatness than any other species with alteration in genes, high calorie diets and environmental factors that predispose humans to obesity. Environmental factors such stress, anxiety and depression are important to consider with the global increase in obesity and is possibly linked to the rise in individuals with mental disorders such as depression. The billion dollar drug industry that targets appetite control in obesity will address issues of post-prandial lipid metabolism and anti-obese drugs that control appetite and will improve post-prandial lipid metabolism that is closely connected to hypercholesterolemia and cardiovascular disease. Various factors effect appetite and brain metabolic diseases and require early intervention with drug therapy to prevent diseases of various organs such as non alcoholic fatty liver disease (NAFLD) in obesity related organ dysfunction. Postprandial lipid metabolism is abnormal in obese individuals and closely connected to the NAFLD and the metabolic syndrome in these individuals. Novel anti-obese designer drugs are involved in regulation of food intake and appetite control linked to cholesterol metabolism and lifespan. Anti-obese drugs regulate genes linked to appetite control and human fatness and are under evaluation in Western countries for the treatment of obesity and diabetes.
|Publication status||Published - 26 Nov 2015|
|Event||Bit's 3rd Annual Global Health Conference-2015 - Kaohsiung, Taiwan, Province of China|
Duration: 26 Nov 2015 → 28 Nov 2015
|Conference||Bit's 3rd Annual Global Health Conference-2015|
|Country||Taiwan, Province of China|
|Period||26/11/15 → 28/11/15|